Swiss National Bank
KYMR icon

Swiss National Bank’s Kymera Therapeutics KYMR Stock Holding History

Swiss National Bank’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.87M Buy
94,500
+300
+0.3% +$23.8K ﹤0.01% 1092
2025
Q4 		$7.33M Buy
94,200
+12,600
+15% +$851K ﹤0.01% 1139
2025
Q3 		$4.62M Buy
81,600
+7,200
+10% +$325K ﹤0.01% 1374
2025
Q2 		$3.25M Sell
74,400
-900
-1% -$31K ﹤0.01% 1524
2025
Q1 		$2.06M Sell
75,300
-900
-1% -$32.8K ﹤0.01% 1745
2024
Q4 		$3.07M Buy
76,200
+10,300
+16% +$465K ﹤0.01% 1601
2024
Q3 		$3.12M Sell
65,900
-24,200
-27% -$1.07M ﹤0.01% 1602
2024
Q2 		$2.69M Buy
90,100
+10,400
+13% +$360K ﹤0.01% 1658
2024
Q1 		$3.2M Buy
79,700
+8,700
+12% +$311K ﹤0.01% 1578
2023
Q4 		$1.81M Sell
71,000
-8,100
-10% -$145K ﹤0.01% 1906
2023
Q3 		$1.1M Buy
79,100
+13,000
+20% +$261K ﹤0.01% 2194
2023
Q2 		$1.52M Sell
66,100
-10,900
-14% -$312K ﹤0.01% 2061
2023
Q1 		$2.28M Sell
77,000
-4,400
-5% -$142K ﹤0.01% 1763
2022
Q4 		$2.03M Buy
81,400
+1,700
+2% +$45.3K ﹤0.01% 1886
2022
Q3 		$1.74M Buy
79,700
+1,000
+1% +$26.4K ﹤0.01% 1967
2022
Q2 		$1.55M Buy
78,700
+11,800
+18% +$276K ﹤0.01% 2095
2022
Q1 		$2.83M Buy
66,900
+5,100
+8% +$215K ﹤0.01% 1828
2021
Q4 		$3.92M Buy
61,800
+1,300
+2% +$75.7K ﹤0.01% 1627
2021
Q3 		$3.55M Buy
60,500
+35,800
+145% +$2.08M ﹤0.01% 1689
2021
Q2 		$1.2M Sell
24,700
-500
-2% -$21.7K ﹤0.01% 2398
2021
Q1 		$979K Hold
25,200
– – ﹤0.01% 2350
2020
Q4 		$1.56M Buy
+25,200
New +$1.23M ﹤0.01% 2057

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Swiss National Bank's KYMR Position: Q1 2026 in Review

Swiss National Bank increased its Kymera Therapeutics (KYMR) stake by 0.32% in Q1 2026, buying an estimated $23.8K and bringing the position to 94,500 shares worth $7.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1092.

Swiss National Bank first reported a position in KYMR in Q4 2020 and has held it in 22 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Swiss National Bank held 94,500 shares of Kymera Therapeutics worth $7.87M as of Q1 2026.
  • Swiss National Bank bought 300 Kymera Therapeutics shares in Q1 2026, an estimated $23.8K.
  • Kymera Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1092 holding.
  • Swiss National Bank first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.